Meet the DNDi network at ECTMIH!

Patient Needs-Driven R&D for Neglected Diseases

• List of Sessions
• Visit our joint DNDi-MSF booth #17

www.dndi.org
MONDAY OCTOBER 3rd

11.00-12.30: Room 1: T1.1 P1 Parallel Session
Global trends in the epidemiology of malaria and advances towards elimination

Speaker (not exhaustive):
- Highlights of the Malaria Elimination research agenda (MalERA)
  Marcel Tanner, Director, Swiss Tropical and Public Health Institute (Swiss TPH); Chair of the Board of Directors, Drugs for Neglected Diseases initiative (DNDi)

11.00-12.30: Room 3: T1.3 M1 Main Session
Improving the quality of diagnostic work-up for neglected tropical diseases, a syndromic approach (NIDIAG)

Speakers (not exhaustive):
- The need for better quality of diagnostic workup in NID
  François Chappuis, Medical Advisor, Médecins Sans Frontières, Switzerland; Associate Professor, Geneva University Hospitals, Switzerland; member of DNDi’s Scientific Advisory Committee
- The febrile syndrome; recent advances in antigen detection tests for visceral leishmaniasis
  Shyam Sundar, Professor of Medicine, Institute of Medical Sciences, Banaras Hindu University, India; key DNDi partner in VL clinical studies

15.00-16.30: Plenary Room: T1.3 M3 Main Session
DNDi’s session: Drug development for Kinetoplastids

Chairs:
- Simon Croft, Professor of Parasitology/Head of Faculty, London School of Hygiene & Tropical Medicine (LSHTM); member of DNDi’s Scientific Advisory Committee
- Jean Jannin, Coordinator, Innovative & Intensified Disease Management, WHO/NTD

Speakers:
- Latest drug development and innovation for kinetoplastid diseases
  Nathalie Strub Wourgaft, Medical Director, Drugs for Neglected Diseases initiative (DNDi)
- HAT: in-hospital safety of NECT use in African children, pregnant and breast-feeding women
  Olaf Valverde, Medical Manager, Drugs for Neglected Diseases initiative (DNDi)
- New drug candidates and innovation for HAT: from discovery to promising candidates, illustrated by Oxaboroles development
  Yves Ribeill, President & CEO, Scynexis
- Chagas portfolio
  Isabela Ribeiro, Head of Chagas Clinical Programme, Drugs for Neglected Diseases initiative (DNDi)
• Treatment modalities for visceral leishmaniasis (Kala-Azar) under field routine program conditions
  Mª Angeles Lima, Tropical Medicine Advisor, Médecins sans Frontières (MSF) NTDs working group

Poster – Session 1 (Monday 3rd until Tuesday 4th)

• Poster #1.3-034: Single-dose Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Fexinidazole
  Antoine Tarral, Séverine Blesson, Olaf Valverde, Lionel Hovsepian, Eric Even, Nathalie Strub Wourgaft

• Poster #1.1-053: Haematological parameters in paediatric uncomplicated falciparum malaria in Sub-Saharan Africa
  Piero Olliaro, Abdoulaye Djimé, Grant Dorsey, Corine Karema, Andreas Mårtensson, Jean-Louis Ndiaye, Sodiomon B Sirima, Michel Vaillant, Julien Zwang

• Poster #1.1-024: Antimalarial drug safety information generated through routine monitoring in a rural health centre in South-western Senegal
  Philippe Brasseur, Malick Badiane, Moustafa Cisse, Patrice Agramey, Michel Vaillant, Piero L Olliaro

TUESDAY OCTOBER 4th

11.00-12.30: Plenary Room T1.3 M4 Main Session
The diagnosis and treatment of leishmaniases (Laboratorios Leti)

Chairs:
• Jorge Alvar, Medical Officer, WHO Leishmaniasis Program, World Health Organization (WHO)
• François Chappuis, Medical Advisor, Médecins Sans Frontières, Switzerland; Associate Professor, Geneva University Hospitals, Switzerland; member of DNDi’s Scientific Advisory Committee

Speakers (not exhaustive):
• Visceral leishmaniasis elimination initiatives in South East Asia and Brazil
  Jorge Alvar, Medical Officer, WHO Leishmaniasis Program, World Health Organization (WHO)
• New perspectives on policies for control of visceral leishmaniasis in India
  Shyam Sundar, Professor of Medicine, Institute of Medical Sciences, Banaras Hindu University, India; key DNDi partner in VL clinical studies
• Treatment of Cutaneous Leishmaniasis: a tri-component approach
  Farrokh Modabber, Senior Advisor for Leishmaniasis, Drugs for Neglected Diseases initiative (DNDi)
12.30 – 14.00: Room 3 T4 P1-09 Parallel Session
Oral communications on health systems and resources

Speaker (not exhaustive):
• Regional Platform to reinforce capacity for clinical trials in Human African Trypanosomiasis (HAT Platform): Five years contributing to improve research
  *Augustin Kadima Ebeja*, Coordinator, HAT Platform, Kinshasa-Congo

16.30-18.00: Room 6 T1.2 M3 Main Session
Institute of Tropical Medicine, Antwerp, Belgium and DNDi session:
Visceral leishmaniasis-HIV coinfection: current challenges and perspectives

Chairs:
• *Jorge Alvar*, Medical Officer, WHO Leishmaniasis Program, World Health Organization (WHO)
• *Ed Zijlstra*, Senior Consultant in Leishmaniasis, Drugs for Neglected Diseases initiative (DNDi)

Speakers:
• Introduction
  *Ed Zijlstra*, Senior Consultant in Leishmaniasis, Drugs for Neglected Diseases initiative (DNDi)
• The Mediterranean experience: lessons learned and current challenges
  *Rogelio López-Vélez*, Associate Professor, Hospital Ramón y Cajal, Madrid
• Experience from the field
  *Koert Ritmeijer*, Health Advisor, Médecins Sans Frontières (MSF)
• VL-HIV coinfection in East-Africa
  *Ermias Diro*, Medical Coordinator, Gondar University, Ethiopia
• VL-HIV coinfection: emerging in South-America
  *José Angelo Lauletta Lindoso*, Researcher, Institute of Infectology Emilio Ribas and Laboratory of Seroepidemiology from Institute of Tropical Medicine from São Paulo, Brazil
• Recent HIV-VL clinical research initiatives in East-Africa
  *Johan van Griensven*, Researcher, ITM Antwerp
• Issues to be addressed and discussion
  *Jorge Alvar*, Medical Officer, WHO Leishmaniasis Program, World Health Organization (WHO)

Poster – Session 1 (Monday 3rd until Tuesday 4th)
• Poster # 1.3-034: Single-dose Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Fexinidazole
  *Antoine Tarral, Séverine Blesson, Olaf Valverde, Lionel Hovsepian, Eric Even, Nathalie Strub Wourgaft*
• **Poster # 1.1-053**: Haematological parameters in paediatric uncomplicated *falciparum* malaria in Sub-Saharan Africa
  
  *Piero Olliaro, Abdoulaye Djimdé, Grant Dorsey, Corine Karema, Andreas Mårtensson, Jean-Louis Ndiaye, Sodiomon B Sirima, Michel Vaillant, Julien Zwang*

• **Poster # 1.1-024**: Antimalarial drug safety information generated through routine monitoring in a rural health centre in South-western Senegal
  
  *Philippe Brasseur, Malick Badiane, Moustafa Cisse, Patrice Agnamey, Michel Vaillant, Piero Olliaro*

**WEDNESDAY OCTOBER 5th**

<table>
<thead>
<tr>
<th>9.00-10.30: Plenary room Plenary Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The Science of Elimination</strong></td>
</tr>
</tbody>
</table>

The debate over what constitutes eradication has been ongoing for decades. In trying to establish clear definitions, a 1997 forum, one in a series of brainstorming sessions called the Dahlem Workshops, stated that “elimination” was to become the word for anything less than the global target, while “eradication” was reserved for pathogens completely out of the world, excluding any remaining stocks in laboratory freezers. Thirty years later, smallpox remains the only human disease to have been truly eradicated. This accomplishment has inspired the global community to aim for other pathogens to be wiped off the planet, and two eradication campaigns for polio and malaria were launched following its wave, although neither has been attained. Today different stakeholders are questioning whether eradication should be our ultimate goal given the resources needed to make it a reality.

Chair:
• *Marcel Tanner*, Director, Swiss Tropical and Public Health Institute (Swiss TPH); Chair of the Board of Directors, Drugs for Neglected Diseases initiative (DNDi)

Speakers:
• *Bernard Pécoul*, Executive Director, Drugs for Neglected Diseases initiative (DNDi)
• *Pedro Alonso*, Professor and Director, Institute for Global Health of Barcelona and Barcelona Centre for International Health Research (Hospital Clinic - University of Barcelona), Spain
• *Lorenzo Savioli*, Director, Department of Control of Neglected Tropical Diseases, World Health Organization (WHO)
• *Rose Leke*, Chair, African Regional Certification Commission
15.00-16.30: Room 3 T1.3 P6 Parallel Session

Other issues in NTDs:

Chair: *To be confirmed*

Speaker (not exhaustive):
- Development of Flubendazole as a macrofilaricide treatment for filarial infections
  *Rob Don*, Discovery & Preclinical Director, Drugs for Neglected Diseases *initiative* (DNDi)

15.00-16.30: Room 4 T1.1 M4 Main Session

Advances and challenges in the treatment of malaria:

Chairs:
- *Tim Wells*, Chief Scientific Officer, Medicines for Malaria Venture (MMV)
- *Nicholas Cammack*, Vice President and Head, GSK Tres Cantos, Spain

Speaker (not exhaustive):
- ASMQ FDC a simple and child friendly ACT developed for Asia and Latin America
  *Jean-René Kiechel*, Senior Pharma Advisor & Product Manager, Drugs for Neglected Diseases *initiative* (DNDi)

16.30-18.00 Room 1 T1.3 P7 Parallel Session

Human trypanosomiasis

Chairs:
- *Faustino Torrico*, Professor of Parasitic Diseases and Infectious Disease, University of San Simon, Bolivia; member of DNDi’s Scientific Advisory Committee
- *Joaquim Gascón*, Head Of Tropical Medicine Section, Barcelona Centre for International Health Research (Hospital Clinic -University of Barcelona), Spain

Speaker:
- Rationale and design of a proof-of-concept Phase II clinical study of E1224, a new drug candidate for chronic Chagas disease
  *Faustino Torrico*, Professor of Parasitic Diseases and Infectious Disease, University of San Simon, Bolivia; member of DNDi’s Scientific Advisory Committee

Poster – Session 2 (Wednesday 5th until Thursday 6th)

- **Poster # 4.3-041**: Three clinical research platforms in Africa and Latin America to build sustainable research capacities
  *Augustin Ebeja*, HAT Platform Coordinator, Drugs for Neglected Diseases *initiative* (DNDi) DRC

- **Poster # 1.3-190**: Population Pharmacokinetics of Benznidazole in Children with Chagas’ Disease
  *Isabela Ribeiro*, Head of Chagas Clinical Programme, Drugs for Neglected Diseases *initiative* (DNDi)
• **Poster # 5.3-036**: Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in Amazon basin communities
  Ana Carolina Santelli, Isabela Ribeiro, André Daher, Marcos Boulos, Paola Marchesini, Roseli La Corte, Marize Barbosa Freire de Lucena, Izanelda Magalhães, Antonio Ponce de Leon, Washington Junger, Jean-René Kiechel, José Lázaro de Brito Ladislau

• **Poster # 1.1-089**: Clinical and laboratory safety of artesunate-amodiaquine and comparator treatments for uncomplicated falciparum malaria - an individual patient data analysis of randomised controlled trials
  Piero Olliaro, JL Ndiaye, SB Sirima, A Mårtensson, A Djimdé, G Dorsey, C Karema, J Zwang

• **Poster # 1.1-091**: Changing malaria patterns - a 15-year study in a rural district of Southern Senegal (1996-2010)
  Michel Vaillant, Piero Olliaro, Moustafa Cisse, Malick Badiane, Philippe Brasseur

• **Poster # 4.3-049**: Health Research policy in southern Sudan
  Richard Lino Lako, Samson Baba, Lea Moja, Ministry of Health Government of Southern Sudan, presented by Augustin Ebeja, DNDi DRC

---

**THURSDAY OCTOBER 6th**

**Poster – Session 2 (Wednesday 5th until Thursday 6th)**

• **Poster # 4.3-041**: Three clinical research platforms in Africa and Latin America to build sustainable research capacities
  Augustin Ebeja, HAT Platform Coordinator, Drugs for Neglected Diseases initiative (DNDi) DRC

• **Poster # 1.3-190**: Population Pharmacokinetics of Benznidazole in Children with Chagas’ Disease
  Isabela Ribeiro, Head of Chagas Clinical Programme, Drugs for Neglected Diseases initiative (DNDi)

• **Poster # 5.3-036**: Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in Amazon basin communities
  Ana Carolina Santelli, Isabela Ribeiro, André Daher, Marcos Boulos, Paola Marchesini, Roseli La Corte, Marize Barbosa Freire de Lucena, Izanelda Magalhães, Antonio Ponce de Leon, Washington Junger, Jean-René Kiechel, José Lázaro de Brito Ladislau

• **Poster # 1.1-089**: Clinical and laboratory safety of artesunate-amodiaquine and comparator treatments for uncomplicated falciparum malaria - an individual patient data analysis of randomised controlled trials
  Piero Olliaro, JL Ndiaye, SB Sirima, A Mårtensson, A Djimdé, G Dorsey, C Karema, J Zwang

• **Poster # 1.1-091**: Changing malaria patterns - a 15-year study in a rural district of Southern Senegal (1996-2010)
  Michel Vaillant, Piero Olliaro, Moustafa Cisse, Malick Badiane, Philippe Brasseur

• **Poster # 4.3-049**: Health Research policy in southern Sudan
  Richard Lino Lako, Samson Baba, Lea Moja, Ministry of Health Government of Southern Sudan, presented by Augustin Ebeja, DNDi DRC
Best science for the most neglected